Engineering small‐molecule analogues of altiratinib via CREB‐regulated transcription co‐activator 3‐target screening for the development of potent and safe topical therapeutics against skin hyperpigmentary diseases
Open Access
- 14 March 2024
- journal article
- research article
- Published by Wiley in Clinical and Translational Medicine
- Vol. 14 (3) , e1625
Abstract
No abstract availableFunding Information
- National Research Foundation of Korea (2020R1A4A4079708, RS‐2023‐00208426, RS‐2023‐00246165)
This publication has 10 references indexed in Scilit:
- CRTC3, a sensor and key regulator for melanogenesis, as a tunable therapeutic target for pigmentary disordersTheranostics, 2021
- Amide Bond Bioisosteres: Strategies, Synthesis, and SuccessesJournal of Medicinal Chemistry, 2020
- Establishment of a mouse model for post‐inflammatory hyperpigmentationPigment Cell & Melanoma Research, 2020
- MITF and UV responses in skin: From pigmentation to addictionPigment Cell & Melanoma Research, 2018
- Novel regulation of melanogenesis by adiponectin via the AMPK/CRTC pathwayPigment Cell & Melanoma Research, 2017
- A comparative study of the in vitro permeation of ibuprofen in mammalian skin, the PAMPA model and silicone membraneInternational Journal of Pharmaceutics, 2016
- Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Molecular Cancer Therapeutics, 2015
- Hypopigmenting agents: an updated review on biological, chemical and clinical aspectsPigment Cell Research, 2006
- The 500 Dalton rule for the skin penetration of chemical compounds and drugsExperimental Dermatology, 2000
- Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene.Molecular and Cellular Biology, 1994